Endocrine late effects from multi-modality treatment of neuroblastoma

H. M. Van Santen, J. De Kraker, T. Vulsma

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

39 Citaten (Scopus)


Thyroid dysfunction has been reported after 131I-MIBG-treatment for neuroblastoma. In this study, we have evaluated all endocrine functions from patients who were given multi-modality treatment including 131I- MIBG. Twenty-five neuroblastoma survivors who were off therapy for a median period of 6.0 years (range 1.3-11.1) were evaluated and their median age was 8.1 years (range 2.2-14.7). All patients had received 131I-MIBG, 16 chemotherapy, and 16 surgery. Fourteen patients (56%) had permanently elevated thyrotropin levels and 9 received thyroxine. Two patients had a small thyroid volume while 6 had thyroid nodules or cysts. Two boys showed hypergonadotropic hypogonadism. Growth was retarded in 39% of children. Mean Target Height Standard Deviation Score of patients with thyrotropin elevation was lower than those without (P = 0.019). Children treated for neuroblastoma with 131I-MIBG, chemotherapy and surgery were seen to be at risk from developing irreversible thyroid function loss, thyroid nodules, hypergonadotropic hypogonadism, and growth retardation. We recommend that during follow-up of neuroblastoma children, special attention should be paid to their endocrine state.

Originele taal-2Engels
Pagina's (van-tot)1767-1774
Aantal pagina's8
TijdschriftEuropean Journal of Cancer
Nummer van het tijdschrift12
StatusGepubliceerd - aug. 2005
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Endocrine late effects from multi-modality treatment of neuroblastoma'. Samen vormen ze een unieke vingerafdruk.

Citeer dit